Categories: News

BioHarvest Sciences Reports Director’s Ongoing Key Role Following Resignation from Board

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – September 20, 2024) – BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (“BioHarvest” or the “Company”), announces the resignation of David Ryan as a director of the Company. Mr. Ryan will remain a key member of the Company’s management team, continuing to serve as Vice President of Investor Relations of the Company.

Mr. Ryan resigned as a director of the Company in order for the Company to meet Nasdaq mandates to have a majority of independent directors in connection with its proposed application to list its common shares on the Nasdaq Stock Market.

On behalf of the Board, we extend our deepest gratitude to David Ryan for his directorship which has been foundational to the development of the Company,” said Zaki Rakib, Board Chair. “His cooperation is a testimony of his continued support and devotion to the Company’s mission and belief.”

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.

BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
+1 (604) 622-1186
info@bioharvest.com

Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group – MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223978

Staff

Recent Posts

Netsmart Showcases Meaningful AI and New Innovations of the CareFabric® Platform to Optimize Community-Based Care at NatCon25

OVERLAND PARK, Kan.--(BUSINESS WIRE)--#Acquisition--Netsmart, an industry-leading provider of healthcare IT for human services and post-acute…

2 hours ago

AV Laboratories Appoints Roula Youssef Halabi to Business Advisory Board to Expand Presence in UAE and Middle East

NEW YORK--(BUSINESS WIRE)--AV Laboratories, a leader in science-backed skincare and luxury skin longevity, proudly announces…

2 hours ago

Eight Student Teams Named National Winners of 33rd Annual ExploraVision Competition

Toshiba and the National Science Teaching Association (NSTA) honor student innovation with prizes and award…

2 hours ago

Psomagen Selected as Key Service Provider, Will Utilize Ultima Genomics’ UG 100™ Sequencer to Accelerate Chan Zuckerberg Initiative’s Billion Cells Project

ROCKVILLE, Md., May 5, 2025 /PRNewswire/ -- Psomagen Inc., a multiomics service laboratory serving academic,…

2 hours ago

Arctic Quest: 8,000-Mile Motorcycle Ride Honors Indigenous Women and Girls

Our Rescue, Mental Health Tech Company and First Nations Advocate Unite to Raise Awareness and…

2 hours ago

Digital Twins in Healthcare Market worth US$59.94 billion by 2030 with 68.0% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., May 5, 2025 /PRNewswire/ -- The global Digital Twins in Healthcare Market,…

2 hours ago